CD8A and acute myeloid leukemia: As an alternative to the CAR T cell approach, we have recently reported on the use of TCR-transduced CD8+ central memory T cells as a delivery vehicle for oncolytic VSV, resulting in an effective combination therapy in a xenograft model of acute myeloid leukemia (AML) in mice.